Premium
The combination of dulaglutide and biguanide reduced bodyweight in J apanese patients with type 2 diabetes
Author(s) -
Inagaki Nobuya,
Araki Eiichi,
Oura Tomonori,
Matsui Akiko,
Takeuchi Masakazu,
Tanizawa Yukio
Publication year - 2016
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12758
Subject(s) - dulaglutide , medicine , insulin glargine , type 2 diabetes , concomitant , gastroenterology , diabetes mellitus , endocrinology , exenatide
The efficacy and safety of once‐weekly dulaglutide 0.75 mg (dulaglutide) in J apanese patients with type 2 diabetes ( T2D ) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents. This exploratory analysis included data from a randomized, open‐label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361). The three subgroups were dulaglutide or glargine in combination with sulphonylurea ( SU ) alone, biguanide ( BG ) alone or SU and BG combined. There were no clinically relevant differences in glycated haemoglobin ( HbA1c ) changes among the three subgroups in the dulaglutide group; in the glargine group, a numerically greater reduction was observed in combination with BG alone compared to the other two groups ( SU alone and SU + BG ). Weight loss was observed with dulaglutide in combination with BG alone or with SU + BG . The incidence of adverse events among subgroups was significantly different in the glargine group but not in the dulaglutide group. Incidence of hypoglycaemia was highest in combination with SU for both treatments. For patients with T2D , dulaglutide added to concomitant BG may be more likely to result in weight loss than dulaglutide added to concomitant SU .